I am a
Home I AM A Search Login

Papers of the Week

2020 May 04

J Clin Oncol

PD-1 Blockade in Anaplastic Thyroid Carcinoma.


Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin C-C, Ramlau R, Butler MO, Delord J-P, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke M L, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, et al.
J Clin Oncol. 2020 May 04:JCO1902727.
PMID: 32364844.


Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor.